Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial by Fanola, Christina L. et al.
Interleukin#6 and the Risk of Adverse
Outcomes in Patients After an Acute
Coronary Syndrome: Observations From
the SOLID#TIMI 52 (Stabilization of
Plaque Using Darapladib—Thrombolysis
in Myocardial Infarction 52) Trial
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Fanola, Christina L., David A. Morrow, Christopher P. Cannon, Petr
Jarolim, Mary Ann Lukas, Christoph Bode, Judith S. Hochman,
Erica L. Goodrich, Eugene Braunwald, and Michelle L. O'Donoghue.
2017. “Interleukin#6 and the Risk of Adverse Outcomes in Patients
After an Acute Coronary Syndrome: Observations From the SOLID#
TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis
in Myocardial Infarction 52) Trial.” Journal of the American Heart
Association: Cardiovascular and Cerebrovascular Disease 6 (10):
e005637. doi:10.1161/JAHA.117.005637. http://dx.doi.org/10.1161/
JAHA.117.005637.
Published Version doi:10.1161/JAHA.117.005637
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34651875
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an
Acute Coronary Syndrome: Observations From the SOLID-TIMI 52
(Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial
Infarction 52) Trial
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Background-—Interleukin-6 (IL-6) is an inﬂammatory cytokine implicated in plaque instability in acute coronary syndrome (ACS).
We aimed to evaluate the prognostic implications of IL-6 post-ACS.
Methods and Results-—IL-6 concentration was assessed at baseline in 4939 subjects in SOLID-TIMI 52 (Stabilization of Plaque
Using Darapladib—Thrombolysis in Myocardial Infarction 52), a randomized trial of darapladib in patients ≤30 days from ACS.
Patients were followed for a median of 2.5 years for major adverse cardiovascular events; cardiovascular death, myocardial
infarction, or stroke) and cardiovascular death or heart failure hospitalization. Primary analyses were adjusted ﬁrst for baseline
characteristics, days from index ACS, ACS type, and randomized treatment arm. For every SD increase in IL-6, there was a 10%
higher risk of major adverse cardiovascular events (adjusted hazard ratio [adj HR] 1.10, 95% conﬁdence interval [CI] 1.01-1.19) and
a 22% higher risk of cardiovascular death or heart failure (adj HR 1.22, 95% CI 1.11-1.34). Patients in the highest IL-6 quartile had a
higher risk of major adverse cardiovascular events (adj HR Q4:Q1 1.57, 95% CI 1.22-2.03) and cardiovascular death or heart failure
(adj HR 2.29, 95% CI 1.6-3.29). After further adjustment for biomarkers (high-sensitivity C-reactive protein, lipoprotein-associated
phospholipase A2 activity, high-sensitivity troponin I, and B-type natriuretic peptide), IL-6 remained signiﬁcantly associated with the
risk of major adverse cardiovascular events (adj HR Q4:Q1 1.43, 95% CI 1.09-1.88) and cardiovascular death or heart failure (adj
HR 1.79, 95% CI 1.22-2.63).
Conclusions-—In patients after ACS, IL-6 concentration is associated with adverse cardiovascular outcomes independent of
established risk predictors and biomarkers. These ﬁndings lend support to the concept of IL-6 as a potential therapeutic target in
patients with unstable ischemic heart disease. ( J Am Heart Assoc. 2017;6:e005637. DOI: 10.1161/JAHA.117.005637.)
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I nitiation and progression of subclinical atherosclerosis toplaque instability and rupture in acute coronary syndrome
(ACS) comprise a complex process driven by both vascular
lipoprotein accumulation and inﬂammation.1 Interleukin-6
(IL-6) is a cytokine that has been implicated in vascular
inﬂammation2 and the initiation and progression of
atherosclerosis and degradation of the ﬁbrous cap contribut-
ing to plaque instability.3,4 IL-6 propagates inﬂammation and
promotes hepatic hs-CRP (high-sensitivity C-reactive protein)
production. Prior studies have demonstrated that higher
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concentrations of IL-6 are associated with worse vascular
health in individuals without clinical atherosclerosis and are
associated with the risk of future myocardial infarction (MI).5,6
In patients with ST-elevation MI (STEMI), IL-6 has been shown
to be upregulated at the site of coronary occlusion.7,8 It has
also been suggested that IL-6 concentration may be useful for
identifying those patients with unstable coronary disease who
may beneﬁt more from an invasive strategy.9
Interest in IL-6 as a potential therapeutic target is
supported by Mendelian randomization studies that have
shown signaling through the IL-6 receptor to be directly
implicated in the development of coronary heart disease.10
Moreover, blockade of the IL-6 receptor with tocilizumab has
been shown to attenuate inﬂammation and blunt the peripro-
cedural rise in troponin in patients with non-ST-elevation MI.11
However, the relationship of IL-6 with outcomes in patients
after ACS remains incompletely deﬁned. This relationship
remains of importance because of interest in the IL-1/IL-6/
CRP axis as a potential therapeutic target.11,12 As an
exploratory analysis, we therefore evaluated the association
of IL-6 with cardiovascular outcomes in a large randomized
trial population of an anti-inﬂammatory therapeutic in patients
after ACS.
Methods and Materials
Study Population
The SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-
Thrombolysis in Myocardial Infarction 52) study design and
trial results have been previously published.13,14 In brief, the
trial population enrolled 13 026 moderate- to high-risk
patients across 36 countries within 30 days of hospitalization
with an ACS (unstable angina, non-ST-elevation MI , or STEMI).
Patients were randomly allocated to once-daily oral darapladib
(an inhibitor of the proinﬂammatory enzyme lipoprotein-
associated phospholipase A2) or matching placebo in a
double-blinded manner. The use of guideline-recommended
therapies was strongly encouraged throughout the duration of
the trial through the routine distribution of performance
reports to sites and country leaders. The median duration of
follow-up was 2.5 years.
Biomarker and Chemistry Assessment
Serum and plasma samples were collected at baseline in
randomly selected patients and stored at 20°C or colder for
less than 6 weeks and then shipped on dry ice to the TIMI
Clinical Trials Laboratory where they were then stored at
70°C or colder. Routine blood chemistries and lipoprotein-
associated phospholipase A2 activity (diaDexus, Poway, CA)
were assessed in all patients at baseline (median 14 days
after ACS). Each of the following biomarkers were also
assayed in a randomly selected, planned cohort of 5000
patients: IL-6 (Erenna Immunoassay, Singulex, Inc, Palo Alto,
CA), high-sensitivity troponin I (hsTnI) and B-type natriuretic
peptide (BNP, Architect i2000SR; Abbott Laboratories, Abbott
Park, IL), and hsCRP (cobas 6000; Roche Diagnostics, Basel,
Switzerland).
End Point Assessment
The primary end point for the trial was the composite of
coronary heart disease death, MI, or urgent coronary revas-
cularization for myocardial ischemia (major coronary events).
Prespeciﬁed end points of interest for this analysis included
the composite of cardiovascular death, MI, or stroke (major
adverse cardiovascular events, MACE), and the composite of
cardiovascular death or hospitalization for heart failure (HF).
Individual components of the composite end points were also
assessed. All events in this analysis were adjudicated by a
blinded Clinical Events Committee.
Statistical Methods
Baseline characteristics were examined by IL-6 quartiles.
Multilevel and single-level categorical variables were assessed
by v2 and Cochran Armitage trend tests, respectively, and
continuous variables with the Jonckheere-Terpstra test. The
correlation between IL-6 and established biomarkers was
evaluated with the Spearman correlation test. Median
concentrations of IL-6 were compared with the Kruskal-Wallis
test in those with and without the outcomes of interest.
Clinical Perspective
What Is New?
• Interleukin-6 (IL-6) is an inﬂammatory cytokine implicated in
plaque instability in acute coronary syndromes. However,
it’s prognostic relevance in patients after an acute coronary
syndrome has remained unclear.
• We determined that IL-6 is associated with an increased risk
of major adverse cardiovascular events including heart
failure.
• This relationship was independent of established clinical
predictors and risk markers including hsCRP, Lp-PLA2
activity, hsTnI, and BNP.
What Are the Clinical Implications?
• The inﬂammatory cytokine IL-6 may be useful for risk
stratiﬁcation in patients after an acute coronary syndrome.
• These ﬁndings lend support to studies that are investigating
a possible role for interleukin-6 as a therapeutic target in
patients with unstable coronary artery disease.
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Table 1. Baseline Characteristics Stratiﬁed by IL-6 Quartile
Baseline Characteristic
N (%)
P Value
Quartile 1 (≤1.16 pg/mL)
N=1236
Quartile 2 (1.16-2.02 pg/mL)
N=1236
Quartile 3 (2.02-3.97 pg/mL)
N=1233
Quartile 4 (>3.97 pg/mL)
N=1234
Age, median (IQR) 63 (57, 69) 65 (60, 71) 64 (59, 71) 65 (60, 72) <0.001
BMI, kg/m2, median (IQR) 26.9 (25.1, 30.1) 28.1 (25.1, 31.8) 28.2 (25.3, 31.6) 27.7 (25.1, 31.2) <0.001
Female 287 (23.2) 324 (26.2) 319 (25.9) 345 (28.0) 0.013
Race 0.013
White 1064 (86.1) 1082 (87.5) 1103 (89.5) 1094 (88.7)
Black 28 (2.3) 29 (2.3) 32 (2.6) 37 (3.0)
Asian 128 (10.4) 98 (7.9) 84 (6.8) 83 (6.7)
Other 16 (1.3) 27 (2.2) 14 (1.1) 20 (1.6)
Region <0.001
North America 352 (28.5) 302 (24.4) 250 (20.3) 215 (17.4)
South America 91 (7.4) 108 (8.7) 105 (8.5) 88 (7.1)
Western Europe 316 (25.6) 339 (27.4) 386 (31.3) 448 (36.3)
Eastern Europe 346 (28.0) 376 (30.4) 397 (32.2) 370 (30.0)
Asian Pacific 131 (10.6) 111 (9.0) 95 (7.7) 113 (9.2)
Current smoker 161 (13.0) 203 (16.4) 267 (21.7) 275 (22.3) <0.001
Hypertension 878 (71.0) 929 (75.2) 935 (75.8) 916 (74.2) 0.066
Hyperlipidemia 840 (68.0) 827 (66.9) 813 (65.9) 755 (61.2) <0.001
Diabetes mellitus 379 (30.7) 419 (33.9) 456 (37.0) 416 (33.7) 0.042
eGFR <60 mL/min per 1.73 m2 93 (7.6) 131 (10.7) 168 (13.9) 194 (16.1) <0.001
History of PAD 82 (6.6) 120 (9.7) 100 (8.1) 136 (11.0) 0.001
Prior MI 423 (34.2) 401 (32.4) 368 (29.8) 363 (29.4) 0.004
Prior PCI 320 (25.9) 304 (24.6) 292 (23.7) 249 (20.2) <0.001
Qualifying event
STEMI 475 (38.4) 522 (42.2) 576 (46.7) 669 (54.2) <0.001
UA 198 (16.0) 165 (13.3) 129 (10.5) 101 (8.2) <0.001
NSTEMI 563 (46.0) 549 (44.4) 528 (42.8) 464 (37.6) <0.001
Days from event 20 (13, 26) 17 (9, 24) 12 (5, 21) 6 (3, 13) <0.001
PCI 915 (74.0) 918 (74.3) 928 (75.3) 990 (80.2) <0.001
Fibrinolytics 113 (9.1) 103 (8.3) 108 (8.8) 117 (9.5) 0.70
CAD anatomy <0.003
One-vessel 505 (48.4) 474 (46.3) 424 (40.5) 445 (41.0)
Two-vessel 293 (28.1) 300 (29.3) 348 (33.3) 357 (32.9)
Three-vessel 245 (23.5) 249 (24.3) 274 (26.2) 284 (26.2)
Medications
Aspirin 1205 (97.5) 1175 (95.1) 1196 (97.0) 1199 (97.2) 0.68
P2Y12 Inhibitor 1086 (87.9) 1066 (86.2) 1090 (88.4) 1125 (91.2) 0.003
b-Blocker 1059 (85.7) 1099 (88.9) 1101 (89.3) 1086 (88.0) 0.075
ACEI or ARB 994 (80.4) 1049 (84.9) 1027 (83.3) 1036 (84.0) 0.058
Statin 1171 (94.7) 1160 (93.9) 1178 (95.5) 1173 (95.1) 0.35
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular ﬁltration
rate in mL/min per 1.73 m2; IQR, interquartile range; MI, myocardial infarction; NSTEMI, non-ST-elevation MI; PAD, peripheral artery disease; PCI, percutaneous coronary intervention;
STEMI, ST-elevation MI; UA, unstable angina.
*Continuous variables are presented as medians (interquartile range) and categorical as numbers (percentages).
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Kaplan-Meier rates are reported at 3 years. As a sensitivity
analysis, a landmark analysis was performed beyond 30 days
in order to assess the long-term association of IL-6 with
recurrent cardiovascular events following the early inﬂamma-
tory response after ACS.
The risk of cardiovascular outcomes associated with IL-6
quartiles and log-transformed IL-6 concentration was exam-
ined with Cox proportional hazards modeling. The generated
hazard ratios (HR) and 95% conﬁdence intervals (CI) were
adjusted for age, sex, race (white versus nonwhite), smoking
status, diabetes mellitus, body mass index, hypertension,
hyperlipidemia, baseline low-density lipoprotein levels, prior
MI, prior percutaneous coronary intervention, index event (ST-
elevation ACS or STEMI versus non-ST-elevation ACS), days
from index event, estimated glomerular ﬁltration rate
<60 mL/min per 1.73 m2, peripheral artery disease, and
randomized treatment arm. Of 4939 patients in the biomarker
substudy, 4720 (96%) had complete data available for
multivariate analysis. The model was subsequently adjusted
for established biomarkers, including hsTnI, hsCRP, lipopro-
tein-associated phospholipase A2 and BNP. A sensitivity
analysis was conducted that included left ventricular ejection
fraction in the model (available in 84.1% of study population).
The interaction between IL-6 and the treatment beneﬁt of
darapladib was examined by including an interaction term in
the models. An additional sensitivity analysis was stratiﬁed by
index diagnosis (NSTE-ACS and STEMI). This was an obser-
vational study from a randomized clinical trial cohort. Because
this analysis was exploratory, no formal adjustments for
multiplicity were performed.
Results
The baseline characteristics of the randomly selected
biomarker cohort (n=4939) versus the overall trial population
are shown in Table S1. The median baseline IL-6 concentra-
tion was 2.02 pg/mL (25th and 75th percentiles 1.16 and
3.97 pg/mL, respectively) when assessed a median of
14 days from the qualifying ACS event. No samples had
IL-6 values below the lowest detectable level of 0.158 pg/mL.
In general, higher concentrations of IL-6 were associated
with female sex, white race, current smoking, diminished
renal function (estimated glomerular ﬁltration rate <60 mL/
min per 1.73 m2), peripheral artery disease, and more
diseased coronary vessels at catheterization. Patients with
higher concentrations of IL-6 were signiﬁcantly more likely to
have STEMI as their index event and to have been enrolled in
Western or Eastern Europe. Lower IL-6 concentrations were
associated with hyperlipidemia and prior MI (Table 1). The use
of evidence-based therapies was high across groups and the
use of statins, aspirin, b-blockers, angiotensin-converting
enzyme inhibitors, or angiotensin II receptor blockers at
baseline did not signiﬁcantly vary across IL-6 quartiles.
However, patients with higher IL-6 concentrations were
signiﬁcantly more likely to undergo percutaneous coronary
intervention for the qualifying event and be on a P2Y12
inhibitor. There were modest to strong correlations between
IL-6 and hsTnI (r=0.48, P<0.001) and hsCRP (r=0.71,
P<0.001), and a weaker correlation between IL-6 and BNP
(r=0.24, P<0.001).
IL-6 Concentration and Risk of Cardiovascular
Events
Median IL-6 concentrations were signiﬁcantly higher for
patients who subsequently experienced MACE, cardiovascular
death or HF, and individual components during long-term
follow-up, compared with patients without an event (Table 2).
A stepwise increase in the risk of MACE was seen across
quartiles of IL-6 (P trend<0.0001; Figure 1), including the
individual components of cardiovascular death (P trend
<0.0001) and MI (P trend=0.016) but not stroke (P
trend=0.19). Similarly, a stepwise increase in the risk of
cardiovascular death or HF (P trend <0.0001) and its
components was seen with increasing IL-6 concentration
(Figure 1). A landmark analysis demonstrated consistency of
Table 2. Median IL-6 Concentration by Long-Term Cardiovascular End Points
End Point
N (%)
N=4939
Median IL-6 Level (IQR), pg/mL
P ValueWithout Event With Event
MACE 644 (13.0) 2.0 (1.1, 3.9) 2.4 (1.3, 4.5) <0.001
Cardiovascular death or HF 342 (6.9) 2.0 (1.1, 3.9) 2.7 (1.5, 5.5) <0.001
Cardiovascular death 204 (4.1) 2.0 (1.1, 3.9) 2.8 (1.5, 5.2) <0.001
Myocardial infarction 401 (8.1) 2.0 (1.1, 3.9) 2.4 (1.3, 4.2) 0.03
Stroke 117 (2.3) 2.0 (1.2, 3.9) 2.2 (1.3, 4.3) 0.4
HF hospitalization 182 (3.7) 2.0 (1.1, 3.9) 2.9 (1.6, 6.0) <0.001
HF indicates heart failure; IQR, interquartile range; MACE, major adverse cardiovascular events including cardiovascular death, myocardial infarction, or stroke.
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these ﬁndings when the analysis period was restricted to
beyond 30 days following randomization (Figure 2).
After adjusting for baseline characteristics and clinical
predictors, there was a 10% higher risk of MACE (adjusted
hazard ratio [adj HR] 1.10, 95% CI 1.01-1.19), 24% higher
risk of coronary heart disease (CHD) death (adj HR 1.24,
95% CI 1.09-1.41), and a 22% higher risk of cardiovascular
death or HF (adj HR 1.22, 95% CI 1.11-1.34) for each SD
increase in log-transformed IL-6. Patients with the highest IL-
6 concentrations had a 57% higher risk of MACE (adj HR Q4:
Q1 1.57, 95% CI 1.22-2.03), more than 2-fold higher risk of
cardiovascular death or HF (adj HR 2.29, 95% CI 1.6-3.29)
as well as a higher risk of cardiovascular death (adj HR 2.13,
95% CI 1.35-3.36), MI (adj HR 1.39, 95% 1.01-1.93) and HF
(adj HR 3.1, 95% CI 1.81-5.33) (Table 3). After further
adjustment for established markers (hsCRP, BNP, hsTnI, and
lipoprotein-associated phospholipase A2 activity), IL-6
remained signiﬁcantly associated with the risk of MACE
(adj HR Q4:Q1 1.43, 95% CI 1.09-1.88) and cardiovascular
death or HF (adj HR 1.79, 95% CI 1.22-2.63) (Figure 3). In
the subset of patients who had an assessment of left
ventricular ejection fraction during their index hospitaliza-
tion, inclusion of this factor in multivariable models yielded
similar results (Table S2). Directionally consistent results
were observed across both the STEMI and non-ST-elevation
ACS populations (Tables S3 and S4, Figures S1 and S2). The
magnitude of the relationship between IL-6 and cardiovas-
cular outcomes appeared to be stronger in STEMI than in
non-ST-elevation ACS patients (MACE, P interaction=0.05;
cardiovascular death or HF, P interaction=0.001). Overall,
the investigational therapy darapladib did not reduce the
primary outcome of CHD death, MI, or urgent coronary
revascularization for myocardial ischemia (HR 1.0, 95% CI
0.91-1.09). Consistent with the overall trial results, IL-6
concentration did not identify patients who beneﬁted from
darapladib (P-value for interaction=0.57).
Discussion
Our ﬁndings from this exploratory analysis within the SOLID-
TIMI 52 trial demonstrated that in a cohort of patients post-
ACS, IL-6 is associated with increased risk of cardiovascular
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Figure 1. Cumulative 3-year Kaplan-Meier event rates for major cardiovascular end points by IL-6 quartile. CV indicates cardiovascular; CVD,
cardiovascular death; HF, heart failure; KM, Kaplan-Meier; MACE, major adverse cardiovascular events; MI, myocardial infarction.
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events, including recurrent MI, HF, and death, independent of
traditional clinical risk factors and known biomarkers, such as
hsCRP, associated with vascular disease. This heightened risk
emerged early after ACS by 30 days and persisted through a
median 2.5 years of follow-up.
IL-6 and Cardiovascular Risk
The baseline median IL-6 concentration in our ACS popula-
tion was 2.01 pg/mL, which can be compared to a value of
1.46 in a relatively healthy cohort of men without estab-
lished coronary disease.5 IL-6 has been independently linked
to endothelial dysfunction and subclinical atherosclerosis
after adjustment for baseline hsCRP15 and has been shown
to be an important predictor of vascular events in patients
without clinically evident atherosclerosis at baseline.5,6 The
Emerging Risk Factors Collaboration meta-analysis pooled
data from up to 29 cohorts without established coronary
artery disease but with risk factors and demonstrated that
for each SD increase in log-IL-6, there is a 25% increased
risk for incident CHD including CHD death.16 We showed in
patients with established CHD, after adjusting for additional
clinical risk factors and other inﬂammatory biomarkers, that
the risk of CHD death per SD increase in log-IL-6 was
similar.
Compared to its state during stable progression of
subclinical atherosclerosis, the inﬂammatory cascade is
enhanced following ACS.17 Progressive atherosclerosis
involves the recruitment and differentiation of monocytes
within the blood vessel wall, developing into lipid-laden
proinﬂammatory foam cells.17 When these cells subsequently
undergo cell death, they cause a large necrotic lipid core and
release of IL-6 and other cytokines, which is implicated in the
destruction of its ﬁbrous cap and plaque instability that leads
to ACS.17 In the Fragmin during Instability in Coronary Artery
Disease Trial, elevated hsCRP was additive to troponin T levels
in its predictive risk of long-term mortality in patients with
unstable coronary artery disease.18 Similarly, hsCRP was an
independent predictor of poor outcomes post-ACS in the TIMI
11A Trial.19 However, the synthesis of hsCRP is secondary to
upstream interleukin cytokine stimulation in the inﬂammatory
process.
Concurrently elevated IL-6, hsCRP, and NT-proBNP were
found to be independent predictors of 90-day death, shock,
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Figure 2. Kaplan-Meier 30-day landmark analysis for MACE (A) and for cardiovascular death or HF (B) by IL-6 quartiles. CV indicates cardiovascular;
HF, heart failure; KM, Kaplan-Meier;MACE,major adverse cardiovascular events including cardiovascular death,MI or stroke;MI,myocardial infarction.
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or heart failure in patients with STEMI in an APEX-AMI
subgroup analysis.20 The Fragmin and Fast Revasculariza-
tion during Instability in Coronary Artery Disease II trial
demonstrated an absolute reduction of 5.1% in mortality
seen with an early invasive strategy in those with IL-6
concentrations greater than 5 ng/L but no detectable
beneﬁt in patients with lower concentrations.9 In the
current study, the magnitude of the relationship between
IL-6 and cardiovascular outcomes appeared to be stronger
in STEMI than in non-ST-elevation ACS patients, which may
in part suggest that IL-6 reﬂects the inﬂuence of infarct
size. However, we demonstrated that these relationships
remained signiﬁcant when index diagnosis, management
strategy, and left ventricular ejection fraction were consid-
ered in multivariate models. Further, IL-6 was prognostic
beyond the acute phase of the event and was associated
with an increased risk of adverse outcomes through long-
term follow-up. This suggests that IL-6 may have additional
predictive value downstream from the initial infarct. In post-
MI patients the inﬂammatory cascade has been implicated
in altering the coronary vasculature in a diffuse way,
leading to subsequent plaque instability at nonculprit
atherosclerotic lesions and contributing to a risk of
reinfarction and poor cardiovascular outcomes.21-23
Our study also demonstrated that the highest IL-6 quartile
was associated with more than 2-fold increased risk of HF
hospitalization compared to the lowest IL-6 quartiles. IL-6 is
an inducer of matrix metalloproteinase expression,24 a protein
family involved in the upregulation of collagen synthesis,
resulting in progressive ﬁbrosis and cardiac remodeling
known to contribute to the mechanism of heart failure.25 In
addition, with progression of nonculprit atherosclerosis post-
ACS, an increase in diastolic dysfunction is likely to accom-
pany ongoing multivessel ischemia. Our study demonstrated
that despite its association with the risk of HF hospitalization,
IL-6 concentration was only weakly correlated with BNP.
There was no difference in the use of traditional HF therapies
across IL-6 quartiles, such as b-blockers or angiotensin-
converting enzyme inhibitors or aldosterone receptor block-
ers, and therefore, results cannot be explained by an
imbalance in optimal medical therapy.
IL-6 as a Possible Therapeutic Target
Although the hypothesis can only be conﬁrmed through a
clinical trial, the ﬁndings in the present study support the
concept of IL-6 as a potential therapeutic target in ACS.
Tocilizumab, a humanized anti-IL-6 receptor antibody, is
currently under study. The ENTRACTE trial is analyzing the
effects of tocilizumab versus etanercept on the risk of
vascular events in patients with rheumatoid arthritis and a
history of CHD (ClinicalTrials.gov NCT01331837). In phase 2
testing, tocilizumab reduced CRP and demonstrated a trend
toward troponin T reduction in patients with non-ST-elevation
MI,11 and in a recent community-based study in patients with
rheumatoid arthritis has been demonstrated to improve
endothelial function.26 Methotrexate, an anti-inﬂammatory
therapeutic agent used in inﬂammatory arthritis and inhibitor
of the central IL-1/IL-6/CRP axis, is currently under study in
CIRT (the Cardiovascular Inﬂammation Reduction Trial), in
which patients with type 2 diabetes mellitus or metabolic
syndrome and known coronary disease are randomized to
low-dose methotrexate or placebo and followed for MACE.27
Last, the recent CANTOS trial (the Canakinumab Anti-
Inﬂammatory Thrombosis Outcomes Study) studied cardio-
vascular outcomes in stable coronary artery disease patients
with persistently elevated hsCRP (>2 mg/L) randomized to
placebo or canakinumab, an IL-1b inhibitor with upstream
effects on IL-6.12 Results demonstrated a signiﬁcant reduc-
tion in the risk of cardiovascular events with canakinumab.
Prior to this positive trial, however, effective anti-inﬂammatory
therapeutics designed to reduce cardiovascular events have
Table 3. Risk of Cardiovascular Events by IL-6 Quartile Concentration After Adjustment for Clinical Factors
End Point
Hazard Ratio (95% Conﬁdence Interval)
P TrendQuartile 2 (N=1192) Quartile 3 (N=1177) Quartile 4 (N=1168)
MACE 1.22 (0.96-1.55) 1.29 (1.01-1.65) 1.57 (1.22-2.03) 0.0005
Cardiovascular death/HF 1.37 (0.95-1.98) 1.4 (0.96-2.02) 2.29 (1.6-3.29) <0.0001
Cardiovascular death 1.14 (0.71-1.84) 1.4 (0.88-2.23) 2.13 (1.35-3.36) 0.0009
MI 1.18 (0.87-1.59) 1.37 (1.01-1.85) 1.39 (1.01-1.93) 0.029
Stroke 1.17 (0.68-2.0) 0.92 (0.52-1.64) 1.51 (0.85-2.67) 0.28
HF hosp 1.77 (1.02-3.07) 1.66 (0.95-2.9) 3.1 (1.81-5.33) <0.0001
Model adjusted for age, sex, smoking status, body mass index, race (white vs nonwhite), hypertension, diabetes mellitus, peripheral artery disease, estimated glomerular ﬁltration rate
<60 mL/min per 1.73 m2, hyperlipidemia, prior myocardial infarction, percutaneous coronary intervention, index qualifying event (ST-elevation MI vs non-ST-elevation acute coronary
syndrome), days from qualifying event, randomized treatment arm, LDL-cholesterol. HF indicates heart failure; hosp, hospitalization; MACE, major adverse cardiovascular events including
cardiovascular death, MI, or stroke; MI, myocardial infarction.
*Quartile 1 as reference group by Cox Proportional Hazard analysis.
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remained elusive. To that end, the p38 MAP-kinase inhibitor
losmapimod did not improve outcomes in patients hospital-
ized with ACS28 despite favorable effects on IL-6 and
hsCRP.28,29 As a result, challenges continue to exist with
identifying meaningful surrogate end points during the
development of anti-inﬂammatory therapeutics.
Limitations
This study has limitations that warrant consideration. By
design, the SOLID-TIMI 52 trial enrolled patients throughout
the ﬁrst 30 days post-ACS (median 14 days), and it would be
expected that IL-6 concentration would rise acutely at the
time of qualifying event, and may correlate with the size of the
infarct. Left ventricular function was not assessed in all
patients and therefore could not be adjusted for in all models.
However, the observed association between IL-6 and cardio-
vascular risk remained signiﬁcant after adjustment for time
from the index event as well as the type of ACS and other
surrogates of infarct size. Further, the observed results
persisted when events during the ﬁrst 30 days after ACS were
excluded. Although Mendelian randomization studies suggest
a causal role for IL-6 in atherogenesis, the value of IL-6 as a
therapeutic target can only be conﬁrmed through clinical trials
of IL-6 blockade designed speciﬁcally to test the hypothesis.
As with any observational analysis, we cannot exclude the
MACE
CV Death or HF
CV Death
Myocardial Infarcon
Stroke
HF Hospitalizaon
12.9%
14.2%
16.1%
17.3%
Event Rate      Adj. HR (95% CI)
4.6%
7.3%
7.3%
12.5%
3.1%
3.9%
4.7%
7.3%
8.5%
9.0%
11.3%
9.8%
2.8%
2.8%
2.1%
3.8%
1.8%
4.1%
3.7%
7.3%
Reference 
1.15 (0.9-1.47)
1.21 (0.95-1.55)
1.43 (1.09-1.88)
Reference 
1.17 (0.8-1.7)
1.25 (0.86-1.82)
1.79 (1.22-2.63)
Reference 
0.96 (0.59-1.57)
1.26 (0.79-2.01)
1.72 (1.06-2.78)
Reference 
1.13 (0.83-1.54)
1.29 (0.95-1.76)
1.26 (0.89-1.8)
Reference 
1.13 (0.66-1.94)
0.83 (0.46-1.49)
1.34 (0.71-2.5)
Reference 
1.47 (0.84-2.56)
1.46 (0.83-2.56)
2.17 (1.23-3.83)
Hazard Rao 
Increased RiskDecreased Risk
Figure 3. Association of baseline IL-6 quartile with cardiovascular end points after further adjustment
with biomarkers. Adj HR indicates adjusted hazard ratio; CV, cardiovascular; HF, heart failure; KM, Kaplan-
Meier; MACE, major adverse cardiovascular events including cardiovascular death, MI, or stroke. Model
adjusted for age, sex, smoking status, body mass index, race (white vs nonwhite), hypertension, diabetes
mellitus, peripheral artery disease, estimated glomerular ﬁltration rate <60 mL/min per 1.73 m2,
hyperlipidemia, prior myocardial infarction, percutaneous coronary intervention, index qualifying event (ST-
elevation ACS vs non-ST elevation ACS), days from qualifying event, randomized treatment arm, low-density
lipoprotein cholesterol, high-sensitivity C-reactive protrin, lipoprotein-related phospholipase A2, high-
sensitivity troponin I, and B-type natriuretic peptide.
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possibility of residual confounding. Moreover, cut points
employed in the current study will require prospective
validation.
Conclusions
In patients after ACS, IL-6 concentration is signiﬁcantly
associated with the risk of adverse cardiovascular outcomes
independent of established risk predictors and established
biomarkers. Ongoing need exists for clinical trials that target
inﬂammation through IL-6–related pathways, some of which
are now under way in patients with a history of stable
coronary disease. Further study is warranted in patients with
unstable coronary disease patients to mitigate the progres-
sion of culprit and nonculprit disease and improve cardiovas-
cular outcomes.
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Table S1. Baseline Characteristics in Biomarker Population of SOLID – TIMI 52 
Endpoint 
 
 
Total 
Population  
No (%) 
N=13,026 
 
Biomarker 
Sample 
N (%) 
N=4,939 
Non-Biomarker 
Sample  
N (%) 
N=8,087 
P-Value 
Age (yrs, median, IQR) 64 (59, 71) 64 (59, 71) 64 (59, 71) 0.39 
BMI (kg/m2, median, IQR) 27.6 (24.8, 31.1) 27.7 (25.0, 31.2) 27.5 (24.8, 30.9) 0.002 
Female 3326 (25.5) 1275 (25.8) 2051 (25.4) 0.56 
Race 
    White 
    Black 
    Asian 
    Other 
 
10921 (83.8) 
315 (2.4) 
1573 (12.1) 
217 (1.7) 
 
4343 (87.9) 
126 (2.6) 
393 (8.0) 
77 (1.6) 
 
6578 (81.3) 
189 (2.3) 
1180 (14.6) 
140 (1.7) 
<0.001 
 
Region 
    North America 
    South America 
    Western Europe 
    Eastern Europe 
    Asian Pacific 
 
2806 (21.5) 
955 (7.3) 
3688 (28.3) 
3773 (29.0) 
1804 (13.8) 
 
1119 (22.7) 
392 (7.9) 
1489 (30.1) 
1489 (30.1) 
450 (9.1) 
 
1687 (20.9) 
563 (7.0) 
2199 (27.2) 
2284 (28.2) 
1354 (16.7) 
<0.001 
Hypertension 9555 (73.4) 3658 (74.1) 5897 (72.9) 0.15 
Hyperlipidemia 8356 (64.1) 3235 (65.5) 5121 (63.3) 0.013 
Diabetes mellitus 4502 (34.6) 1670 (33.8) 2832 (35.0) 0.16 
Prior MI 4046 (31.1) 1555 (31.5) 2491 (30.8) 0.41 
Prior PCI 3112 (23.9) 1165 (23.6) 1947 (24.1) 0.53 
PAD 1089 (8.4) 438 (8.9) 651 (8.0) 0.10 
eGFR <60 ml/min/1.73 m2 1503 (11.5) 586 (11.9) 917 (11.3) 0.39 
Index Event 
    STEMI 
    NSTEMI 
    Unstable angina 
 
5883 (45.2) 
5559 (42.7) 
1584 (12.2) 
 
2242 (45.4) 
2104 (42.6) 
593 (12.0) 
 
3641 (45.0) 
3455 (42.7) 
991 (12.3) 
0.88 
 
Aspirin 12559 (96.4) 4775 (96.7) 7784 (96.3) 0.27 
P2Y12 Inhibitor 11501 (88.3) 4367 (88.4) 7134 (88.2) 0.80 
Statin 12317 (94.6) 4682 (94.8) 7635 (94.4) 0.42 
Beta Blocker 11364 (87.2) 4345 (88.0) 7019 (86.8) 0.06 
ACEI or ARB 10755 (82.6) 4106 (83.1) 6649 (82.2) 0.21 
*continuous variables are presented as medians (IQR, interquartile range) and categorical as numbers (percentages) 
†BMI, body mass index; eGFR, estimated glomerular filtration rate in ml/min/1.73 m2; PAD, peripheral artery 
disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation MI; NSTEMI, 
non-ST-elevation MI; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. Association of Baseline IL-6 Quartile with Cardiovascular Endpoints after 
Further Adjustment for Left Ventricular Dysfunction 
 
Endpoint 
 
 
 Hazard Ratio (95% Confidence Interval) 
  
P-Trend 
Quartile 2  
(N=998) 
Quartile 3 
(N=1005) 
Quartile 4 
(N=1015) 
MACE 1.20 (0.91-1.58) 1.34 (1.02-1.77) 1.52 (1.11-2.07) 0.006 
CV Death/HF 1.15 (0.76-1.75) 1.25 (0.82-1.90) 1.71 (1.10-2.64) 0.016 
CV Death 1.03 (0.59-1.79) 1.41 (0.83-2.41) 1.83 (1.04-3.19) 0.019 
MI 1.12 (0.79-1.59) 1.43 (1.02-2.01) 1.37 (0.92-2.03) 0.063 
Stroke 1.46 (0.79-2.7) 0.88 (0.44-1.75) 1.36 (0.66-2.81) 0.73 
HF Hosp 1.32 (0.72-2.43) 1.32 (0.72-2.45) 1.96 (1.04-3.68) 0.045 
*Quartile 1 as reference group by Cox Proportional Hazard analysis 
†MACE, major adverse cardiovascular events including CV death, MI or stroke; CV, cardiovascular; HF, heart 
failure; MI, myocardial infarction; Hosp, hospitalization; Model adjusted for age, sex, smoking status, body mass 
index, race (white versus non-white), hypertension, diabetes mellitus, peripheral artery disease, estimated glomerular 
filtration rate < 60 ml/min/1.73m2, hyperlipidemia, prior myocardial infarction, percutaneous coronary intervention, 
index qualifying event (ST-Elevation MI versus non-STE ACS), days from qualifying event, randomized treatment 
arm, LDL-cholesterol, biomarkers (hsCRP, Lp-PLA2, hsTnI, and BNP), and left ventricular dysfunction at 
discharge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3. Adjusted Risk of Cardiovascular Endpoints by Baseline IL-6 Quartile in NSTE 
ACS Population Only 
 
Endpoint 
 
 
 Hazard Ratio (95% Confidence Interval) 
  
P-Trend 
Quartile 2 
(N=694) 
Quartile 3 
(N=631) 
Quartile 4 
(N=539) 
MACE 1.11 (0.84-1.47) 0.95 (0.7-1.28) 1.2 (0.85-1.69) 0.49 
CV Death/HF 1.09 (0.72-1.66) 0.82 (0.52-1.28) 1.18 (0.74-1.88) 0.79 
CV Death 0.95 (0.56-1.63) 0.78 (0.44-1.37) 1.17 (0.65-2.1) 0.78 
MI 1.05 (0.74-1.51) 1.07 (0.73-1.55) 1.07 (0.69-1.66) 0.78 
Stroke 1.14 (0.61-2.11) 0.54 (0.25-1.18) 1.3 (0.6-2.8) 0.98 
HF Hosp 1.26 (0.67-2.37) 1.1 (0.57-2.12) 1.39 (0.70-2.77) 0.43 
* Model adjusted for age, sex, smoking status, body mass index, race (white versus non-white), hypertension, 
diabetes mellitus, peripheral artery disease, estimated glomerular filtration rate < 60 ml/min/1.73m2, hyperlipidemia, 
prior myocardial infarction, percutaneous coronary intervention, days from qualifying event, randomized treatment 
arm, LDL-cholesterol, hsCRP, Lp-PLA2, hsTnI, and BNP with quartile 1 used as referent group 
†NSTE, Non-ST-elevation; ACS, acute coronary syndrome; MACE, major adverse cardiovascular events including 
CV death, MI or stroke; CV, cardiovascular; HF, heart failure; MI, myocardial infarction; Hosp, hospitalization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4. Adjusted Risk of Cardiovascular Endpoints by Baseline IL-6 Quartile in STEMI 
Population Only 
Endpoint 
 
 
 Hazard Ratio (95% Confidence Interval) 
  
P-Trend 
Quartile 2 
N=508 
Quartile 3 
N=552 
Quartile 4 
N=641 
MACE 1.29 (0.79-2.1) 1.86 (1.18-2.95) 1.96 (1.19-3.24) 0.003 
CV Death/HF 1.80 (0.73-4.39) 3.66 (1.60-8.40) 5.33 (2.29-12.39) <0.001 
CV Death 1.19 (0.38-3.74) 3.65 (1.35-9.90) 4.63 (1.66-12.91) <0.001 
MI 1.41 (0.76-2.61) 1.85 (1.03-3.34) 1.68 (0.88-3.22) 0.08 
Stroke 0.95 (0.32-2.84) 1.29 (0.46-3.67) 1.27 (0.40-4.06) 0.59 
HF Hosp 2.46 (0.67-8.97) 3.13 (0.89-11.06) 5.82 (1.65-20.48) 0.005 
* Model adjusted for age, sex, smoking status, body mass index, race (white versus non-white), hypertension, 
diabetes mellitus, peripheral artery disease, estimated glomerular filtration rate < 60 ml/min/1.73m2, hyperlipidemia, 
prior myocardial infarction, percutaneous coronary intervention, days from qualifying event, randomized treatment 
arm, LDL-cholesterol, hsCRP, Lp-PLA2, hsTnI, and BNP with quartile 1 used as referent group 
† STEMI, ST-elevation myocardial infarction; MACE, major adverse cardiovascular events including CV death, MI 
or stroke; CV, cardiovascular; HF, heart failure; MI, myocardial infarction; Hosp, hospitalization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Unadjusted 3-Year Kaplan-Meier Event Rates of Cardiovascular Endpoints by 
Baseline IL-6 Quartile in NSTE-ACS Population Only 
 
 
 
 
NSTE, Non-ST-elevation; ACS, acute coronary syndrome; MACE, major adverse cardiovascular 
events; CV, cardiovascular; MI, myocardial infarction; HF, heart failure; CVD, cardiovascular 
death 
 
 
 
 
 
 
 
 
Figure S2. Unadjusted 3-Year Kaplan-Meier Event Rates of Cardiovascular Endpoints by 
Baseline IL-6 Quartile in STEMI Population Only 
 
 
 
 
 
STEMI, ST-Elevation myocardial infarction; MACE, major adverse cardiovascular events; CV, 
cardiovascular; MI, myocardial infarction; HF, heart failure; CVD, cardiovascular death 
 
 
 
 
 
 
 
 
 
 
 
 
